- Status:
- Amber
- Decision Date:
- June 2025
Comments
- NICE TA995: Relugolix for treating hormone-sensitive prostate cancer
See shared care guideline
Amber Drug Classifications
- 1: Requiring specialist assessment to enable patient selection and initiation of treatment
search again
